Genenta Science News

Express News | HC Wainwright & Co. Reiterates Buy on Genenta Science, Maintains $25 Price Target

BenzingaMay 13 05:51 ET

Genenta Science Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 635.29% HC Wainwright & Co. → $25 Reiterates Buy → Buy 06/29/2023 341.18% Roth MKM → $15 Assume

BenzingaMay 13 05:49 ET

Analysts Conflicted on These Healthcare Names: Cingulate Inc (CING) and Genenta Science SpA Sponsored ADR (GNTA)

TipRanksMay 10 11:00 ET

Press Release: Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinica

Dow JonesMay 6 06:25 ET

Genenta Science Advances Biotech Endeavors

TipRanksMay 3 17:28 ET

Genenta Science Announces ADS Sales Agreement

TipRanksApr 26 18:27 ET

Genenta Science Announces Board Restructuring

TipRanksApr 8 17:27 ET

Genenta Science Announces Shareholder Meeting

TipRanksApr 2 17:59 ET

Genenta Science's Loyalty Shares: A Double-Edged Sword for ADS Liquidity and Investor Influence?

TipRanksMar 31 02:01 ET

12 Health Care Stocks Moving In Monday's Intraday Session

GainersRenalytix (NASDAQ:RNLX) stock rose 490.4% to $2.25 during Monday's regular session. The market value of their outstanding shares is at $112.4 million. Regencell Bioscience (NASDAQ:RGC) stock ro

BenzingaFeb 12 12:31 ET

Buy Rating for Genenta Science SpA on Strong Clinical Prospects and Innovative Gene Therapy Platform

TipRanksFeb 9 12:55 ET

Express News | Genenta Science Has Dosed First Of Three Patients In Cohort 8 (Temferon At 4X10^6/Kg), The Last Cohort Of Phase 1 Dose-ranging Part Of Phase 1/2 Trial In Newly Diagnosed UMGMT Glioblastoma Multiforme Patients; Top Line Data Expected By End Of 2Q24

Moomoo 24/7Feb 8 05:03 ET

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of hematopoietic stem

GlobeNewswireFeb 8 05:00 ET

Genenta to Present at Upcoming Scientific and Investor Conferences

MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem

GlobeNewswireSep 6, 2023 07:00 ET

Genenta Science SpA Sponsored ADR (GNTA) Gets a Buy From H.C. Wainwright

TipRanksJul 28, 2023 10:05 ET

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication MILAN, Italy and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a

GlobeNewswireJul 28, 2023 03:00 ET

Here's Why We're Not Too Worried About Genenta Science's (NASDAQ:GNTA) Cash Burn Situation

Yahoo FinanceJul 8, 2023 09:57 ET

Genenta Science Price Target Announced at $15.00/Share by Roth MKM

Genenta Science Price Target Announced at $15.00/Share by Roth MKM

Dow JonesJun 29, 2023 09:31 ET

Express News | Genenta Science Coverage Assumed by Roth MKM at Buy

Moomoo 24/7Jun 29, 2023 09:31 ET

Roth MKM Assumes Genenta Science at Buy, Announces Price Target of $15

Roth MKM analyst Kumaraguru Raja assumes Genenta Science (NASDAQ:GNTA) with a Buy rating and announces Price Target of $15.

BenzingaJun 29, 2023 09:21 ET